Cas No.: | 1628332-52-4 |
Chemical Name: | 2-[(1-Benzyl-1h-Pyrazol-4-Yl)oxy]pyrido[3,4-D]pyrimidin-4(3h)-One |
Synonyms: | GSK467;GSK 467;2-[(1-Benzyl-1h-Pyrazol-4-Yl)oxy]pyrido[3,4-D]pyrimidin-4(3h)-One;2-[(1-Benzyl-1H-pyrazol-4-yl)oxy]-pyrido-[3,4-d]pyrimidin-4(3H)-one;ZTYRLXUTLYBVHH-UHFFFAOYSA-N;GSK467; GSK 467;BCP30840;J3.601.422I;Q27460958;2-[(1-benzyl-1H-pyrazol-4-yl)oxy]pyrido[3,4-d]pyrimidin-4-ol;2-(1-Benzyl-1H-pyrazole-4-yloxy)-3,4-dihydropyrido[3,4-d]pyrimidine-4-one;GZA |
SMILES: | O(C1=NC2C([H])=NC([H])=C([H])C=2C(N1[H])=O)C1C([H])=NN(C=1[H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H] |
Formula: | C17H13N5O2 |
M.Wt: | 319.3174 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | GSK467 is a selective KDM5 (JARID1) inhibitor with a Ki of 10 nM for KDM5B, shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members[1]. |
References: | [1]. Johansson C, et al. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat Chem Biol. 2016 Jul;12(7):539-45. |